TrialGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2019

A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).

Ken Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.